This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi is increasing focus on innovative medicines while moving away from consumer health. Image credit: Shutterstock/Below the Sky. Sanofi is continuing its immunology pipeline push with an agreement ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13,185.95 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system ...

3 Year-22.72%-13.52% 34.23% 36.41% ...

Shares of Sanofi India gained above 4 percent in early trade on February 28 following its Q4FY25 earnings, as the company reported healthy revenue growth even as profitability faced some ...

Sanofi India Ltd. (SIL) posted steady growth in the fourth quarter of 2024, with revenue increasing by 9.7% year-on-year (YoY) to ₹514.9 crore, compared to ₹469.2 crore in the corresponding quarter of ...